Providing Targeted Cancer Diagnostics

Molecular Pathology Update


HPV Genotyping Service

Zytovision VisionArray HPV Genotyping Assay

Qualitative detection and genotyping of PCR amplicons of 12 high risk, 12 probably high risk, and 17 low risk human papillomavirus (HPV) genotypes

This test is not on our current UKAS (ISO15189:2012) scope of accreditation.

Additional information may be found here: https://www.zytovision.com/products/visionarray


Prosigna Testing Service

Assessment of the PAM 50 gene signature, using the Veracyte Prosigna test.

This test is not on our current UKAS (ISO15189:2012) scope of accreditation.

Additional information may be found here: https://www.prosigna.com/en-gb/

Please contact the laboratory to order this test.


Next Generation Sequencing Service

On the 1st August 2016, the molecular profiling activities undertaken by Advanced Diagnostics transferred to HCA Healthcare, part of HCA Inc. The service was renamed Sarah Cannon Molecular Diagnostics.

This change effected only the molecular profiling service; the Advanced Diagnostics reference laboratory offering clinical immunohistochemical / in-situ hybridization services, now operated by Health Services Laboratories, continues to provide accredited specialist IHC and ISH staining and interpretive services.

Why has ownership changed?

The Advanced Diagnostics Molecular Pathology laboratory based in Shropshire House was created in 2013 in joint partnership between UCL and HCA International and has since become the UK’s largest provider of molecular profiling using next generation sequencing (NGS) and supports the increasing breadth and depth of profiling services offered in both routine cancer diagnostics and oncology clinical trials.

Sarah Cannon Molecular Diagnostics is supported by Sarah Cannon, the global cancer institute of HCA, which offers integrated cancer services with access to cutting-edge therapies for patients across the United States and UK. The UK arm of The Sarah Cannon Research Institute, based in Harley Street, partners with leading pharmaceutical and biotech companies in cancer research; providing a gateway for patients to the latest clinical trials.

The lab is led by Dr Phil Bennett and his team at Ground Floor, Shropshire House, 1 Capper Street London, WC1E 6JA. Contact Phil on 020 3794 1920 or by email at info@sarahcannon-md.co.uk. New website: www.sarahcannon-md.co.uk


Last updated: 21/04/2021